Literature DB >> 31516272

Regression of Fibrosis After Direct-acting Antivirals Treatment of Patients with Hepatitis C Virus Cirrhosis: Transposability to Nondecompensated Patients.

Edoardo G Giannini1, Mattia Crespi1, Mariagiulia Demarzo1, Giorgia Bodini1, Manuele Furnari1, Elisa Marabotto1, Francesco Torre1.   

Abstract

Entities:  

Year:  2018        PMID： 31516272      PMCID： PMC6728531          DOI： 10.1016/j.jceh.2018.10.007

Source DB:  PubMed          Journal:  J Clin Exp Hepatol        ISSN： 0973-6883


× No keyword cloud information.
  4 in total

1.  The 1-year and 3-month prognostic utility of the AST/ALT ratio and model for end-stage liver disease score in patients with viral liver cirrhosis.

Authors:  Edoardo Giannini; Federica Botta; Emanuela Testa; Paola Romagnoli; Simone Polegato; Federica Malfatti; Alessandra Fumagalli; Bruno Chiarbonello; Domenico Risso; Roberto Testa
Journal:  Am J Gastroenterol       Date:  2002-11       Impact factor: 10.864

2.  Sustained virological response to pegylated interferon and ribavirin is maintained during long-term follow-up of chronic hepatitis C patients.

Authors:  E G Giannini; M Basso; V Savarino; A Picciotto
Journal:  Aliment Pharmacol Ther       Date:  2009-11-19       Impact factor: 8.171

3.  Impact of Direct Acting Antiviral Drugs in Treatment Naïve HCV Cirrhosis on Fibrosis and Severity of Liver Disease: A Real Life Experience from a Tertiary Care Center of North India.

Authors:  Gaurav Garg; Vinod K Dixit; Sunit K Shukla; Sudhir K Singh; Shivam Sachan; Anurag Tiwari; Vinod K Yadav; Dawesh P Yadav
Journal:  J Clin Exp Hepatol       Date:  2017-12-06

4.  Sofosbuvir Based Regimen in Management of Hepatitis C for Patients With End Stage Renal Disease on Hemodialysis: A Single Center Experience from India.

Authors:  Ankur Gupta; Puneet Arora; Priyanka Jain
Journal:  J Clin Exp Hepatol       Date:  2017-11-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.